{"id":"tafluprost-ophthalmic-solution-0-0015","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eyelid skin darkening"},{"rate":"5-10%","effect":"Iris pigmentation changes"},{"rate":"5-10%","effect":"Periorbital fat atrophy"},{"rate":"5-10%","effect":"Dry eye"},{"rate":"5-10%","effect":"Eye pain"}]},"_chembl":{"chemblId":"CHEMBL1963683","moleculeType":"Small molecule","molecularWeight":"452.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tafluprost works by mimicking the action of prostaglandin F2α, a naturally occurring substance in the body that helps to regulate intraocular pressure. By increasing uveoscleral outflow, tafluprost reduces the amount of fluid in the eye, thereby lowering intraocular pressure. This mechanism of action is similar to other prostaglandin analogues used to treat glaucoma and ocular hypertension.","oneSentence":"Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:17.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma, ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03822559","phase":"PHASE3","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2019-01-20","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":219},{"nctId":"NCT04737928","phase":"NA","title":"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2018-04-02","conditions":"Glaucoma, Primary Open Angle","enrollment":1},{"nctId":"NCT04654611","phase":"PHASE4","title":"Tafluprost Preservative Free Switch Study","status":"COMPLETED","sponsor":"Tun Hussein Onn National Eye Hospital","startDate":"2019-02-01","conditions":"Glaucoma, Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":28},{"nctId":"NCT04461249","phase":"","title":"Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2019-06-01","conditions":"Primary Open Angle Glaucoma","enrollment":60},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01654484","phase":"PHASE1, PHASE2","title":"A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2012-07","conditions":"Glaucoma and Ocular Hypertension","enrollment":60},{"nctId":"NCT02102750","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":17},{"nctId":"NCT03104621","phase":"PHASE4","title":"Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2013-03","conditions":"Primary Open-angle Glaucoma","enrollment":20},{"nctId":"NCT01342081","phase":"PHASE3","title":"DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":489},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01162603","phase":"PHASE4","title":"Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2011-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":40},{"nctId":"NCT00966940","phase":"PHASE4","title":"Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-09","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT00918346","phase":"PHASE3","title":"Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2005-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tafluprost ophthalmic solution 0.0015%","genericName":"Tafluprost ophthalmic solution 0.0015%","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow. Used for Glaucoma, ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}